$168.73
Value $5.4B
BCPC and CRH stock compared: price, dividend, valuation and results, from SEC filings.
$168.73
Value $5.4B
$92.58
Value $61.9B
Balchem (BCPC) has a market value of $5.4B and CRH (CRH) $61.9B. Over the last year, with dividends, BCPC moved +9.2% and CRH -13.9%. The P/E is 31.6 for BCPC and 17.4 for CRH. Dividend yield: BCPC none, CRH 1.69%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
BCPC$5.4B
CRH$61.9B
CRH is 11 times BCPC
Revenue, 12 months
BCPC$1.1B
CRH$39.0B
CRH is 35 times BCPC
Net income, 12 months
BCPC$171M
CRH$3.6B
CRH is 21 times BCPC
Operating margin
BCPC20.7%
CRH13.7%
7.0 points apart
ROIC
BCPC13.8%
CRH9.2%
4.6 points apart
P/E
BCPC31.6
CRH17.4
BCPC is 1.8 times CRH
Dividend yield
BCPC0.0%
CRH1.7%
1.7 points apart
5-year return
BCPC+3.4%
CRH+109.9%
106.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
BCPC+3.4%
CRH+109.9%
| Period | BCPCWith dividends | CRHWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +9.2%Price +8.5% | -13.9%Price -15.3% |
| 3 years since November 17, 2023 | +40.1%+11.9% a yearPrice +37.8% | +62.5%+17.6% a yearPrice +53.8% |
| 5 years since November 17, 2021 | +3.4%+0.7% a yearPrice +0.7% | +109.9%+16.0% a yearPrice +83.7% |
| 10 years since November 18, 2016 | +126.9%+8.5% a yearPrice +115.2% | +256.5%+13.6% a yearPrice +174.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
BCPCBalchemCRHCRH
| Price | $168.73 | $92.58 |
|---|---|---|
| Market value | $5.4B | $61.9B |
| Enterprise value (EV) | $5.5B | $77.0B |
| P/E | 31.6 | 17.4 |
| P/E, 5-year median | 41.5 | 16.0 |
| P/B | 4.1 | 2.5 |
| EV/EBIT | 23.8 | 14.4 |
| Free cash flow yield | 3.3% | 4.1% |
| Revenue, 12 months | $1.1B | $39.0B |
|---|---|---|
| Net income, 12 months | $171M | $3.6B |
| Free cash flow, 12 months | $178M | $2.5B |
| Earnings per share, 12 months | $5.31 | $5.32 |
| Revenue growth, year on year | 8.8% | 5.3% |
| Revenue growth a year, past | +8.1%over 5 years | +7.7%over 5 years |
| EPS growth a year, past | +12.8%over 5 years | -47.8%over 5 years |
| Gross margin | 36.5% | 36.2% |
|---|---|---|
| Operating margin | 20.7% | 13.7% |
| Net margin | 15.4% | 9.2% |
| ROIC | 13.8% | 9.2% |
| ROE | 13.2% | 15.0% |
| Cash | $66M | $5.1B |
|---|---|---|
| Total debt | $142M | $21.6B |
| Net debt / EBITDA | 0.2 | 2.0 |
| Interest cover | – | 6.3× |
| Dividend yield | – | 1.7% |
|---|---|---|
| Dividend per share, 12 months | – | $1.56 |
| Dividend growth a year, past | +11.1%over 5 years | – |
| Buyback yield | 2.0% | 1.9% |
| Shareholder yield | 2.0% | 3.6% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, CRH ($61.9B) is about 11.4 times Balchem ($5.4B), at today's prices.
Since November 18, 2016, BCPC's price moved +115.2% and CRH's +174.5%. With dividends: BCPC +126.9% (+8.5% a year), CRH +256.5% (+13.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Balchem and 1.69% for CRH. Over the last twelve months they paid – and $1.56 per share.
At today's price, the P/E is 31.6 for BCPC and 17.4 for CRH. The median of the last five years was 41.5 and 16.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 15.4% for Balchem and 9.2% for CRH, and the operating margin 20.7% and 13.7%. Revenue was $1.1B and $39.0B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.